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Abstract
Due to supporting evidence that dietary patterns may have a significant role in the maintenance of good phys-
ical performance with aging, we tested whether plasma fatty acids, saturated fatty acids (SFA), and polyun-
saturated (PUFA) fatty acids are cross-sectionally associated with different physical performance and predict
changes in physical performance over a 3-year period. Data were from the InCHIANTI study, a population-
based study of older Italians. Plasma fatty acids were measured at enrollment (1998–2000), and outcome vari-
ables, Summary Physical Performance Battery (SPPB), and time to walk 7 meters (m) were measured at en-
rollment and after 3 years (2001–2004). At enrollment, 330 participants had significantly impaired lower
extremity performance (defined as a SPPB score 9). Adjusting for age, participants with a SPPB score 9 had
higher levels of total PUFA, n-3 PUFA, and n-6 PUFA, while significantly lower levels of SFA than those with
a SPPB score 9. Baseline SPPB scores were also associated with n-3 PUFA (  0.148, p  0.031), whereas the
7-m walk time was associated with total PUFA (  0.068, p  0.008), after adjusting for potential confounders.
Of the 884 participants with a SPPB score 9 at baseline, 114 (12.9%) developed impaired lower extremity per-
formance (SPPB 9). In fully adjusted logistic models, baseline n-3 PUFA levels were inversely related to the
risk of developing a decline in SPPB to 9 (odds ratio [OR]  0.21; 95% confidence interval [CI]  0.08–0.53),
while the n-6/n-3 ratio was associated with a higher risk of SPPB decline to 9 (OR  5.23; 95% CI  2.02–13.51).
In multivariate regression models, the n-6/n-3 ratio was associated with a longer time to walk 7 m (   0.396,
p  0.037). n-3 PUFA plasma levels, which most likely reflect dietary intake, seem to protect against acceler-
ated decline of physical performance. A higher n-6/n-3 ratio was associated with higher risk of developing
poor physical performance and slower walking speed.
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Introduction
DISABILITY IS A COMMON CONDITION in older persons and,although a decline in age- and sex-specific rates of dis-
ability has been recently observed,1 the absolute number of
disabled older persons will continue to increase in the next
decades due to aging of the population, causing massive in-
creases of health-care costs.2 A decline in physical perfor-
mance often marks the early stage of the process leading to
disability in older persons.3 Therefore, understanding the
mechanisms that are responsible for the age-associated de-
cline in performance is paramount to design preventive in-
terventions.
Several factors have been associated with maintenance of
a good physical performance in older persons, including
physical activity and exercise4 as well as low levels of in-
flammatory markers.5 Recently, diet has been evaluated as
a potential protective factor against the risk of developing
physical performance decline. Studies have shown that nu-
tritional factors, such as carotenoids6 and antioxidant vita-
mins C7 and E7,8 are associated with higher muscle strength,
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better physical performance, and/or reduced risk of physi-
cal function decline in older subjects.
Several lines of evidence suggest that polyunsaturated
fatty acids of the n-3 family have strong anti-inflammatory
activity9 and therefore may be beneficial for the treatment of
diseases associated with an increased inflammatory state and
subsequent catabolic state, such as muscle mass loss and im-
pairment of physical performance.10 A member of the n-3
fatty acids, eicosapentanoic acid (EPA) was shown to pre-
vent weight loss11 and to increase total energy expenditure
with a parallel improvement in the physical function in can-
cer patients.12 In a small clinical trial, polyunsaturated fatty
acids (PUFAs) improved exercise capacity in patients with
chronic obstructive pulmonary disease.13 However, it is not
known whether levels of circulating fatty acids are signifi-
cant predictors on the risk of physical function decline. If this
hypothesis is confirmed, a role for a diet rich in PUFAs
against age-related decline of lower extremity function may
be hypothesized.
Plasma fatty acids are good markers of dietary intake,14
and they also considered biomarkers for long-term essential
fatty acid intake because their levels change in parallel with
changes in fatty acid composition of adipose tissue.15 There-
fore, the aim of this study is to investigate whether plasma
fatty acids (both saturated and polyunsaturated) are cross-
sectionally associated with objectively measured lower ex-
tremity performance and predict accelerated decline of lower




This research is part of the InCHIANTI study, a prospec-
tive population-based study of older persons originally de-
signed by the laboratory of Clinical Epidemiology of the Ital-
ian National Research Council of Aging, (INRCA, Florence,
Italy) and carried out in the Chianti geographic area in Tus-
cany, Italy. The InCHIANTI database includes data from
1453 participants (between 22 and 104 years of age) ran-
domly selected from the residents in the two municipalities
of Greve in Chianti and Bagno a Ripoli using a multistage
stratified sampling method.16 Baseline data collection started
in September, 1998, and was completed in March, 2000; the
first follow up started in November, 2001, and was com-
pleted in April, 2003. All subjects gave their informed con-
sent before participating in the study, which was approved
by the ethical committee of our institutions. For participants
who were unable to provide a full consent, because of cog-
nitive or communication impairment, we obtained an assent
and surrogate consent from a proxy.
The baseline population for this study included 1273 par-
ticipants between 22 and 104 years of age, selected from the
cohort from Greve and Bagno a Ripoli because they had
complete data on fatty acids and lower extremity perfor-
mance. At follow up, we considered only those participants
having full data sets for study purposes (n  884).
Laboratory analysis
Blood samples were collected in the morning after the par-
ticipants had been fasting for at least 8 h. Aliquots of serum
and plasma were immediately stored at 80°C. The samples
used to measure cytokines and fatty acids had not been pre-
viously thawed. Fatty acids were measured using a fasting
plasma sample.
A detailed description of the assay for fatty acids has been
already described in detail.9 A known amount of heptade-
canoic acid (17:0) (Sigma Chemical Co., St. Louis) was added
to each sample as an internal standard, and total lipids were
extracted from 0.15 mL of plasma. In a pilot study, we found
that no traces of heptadecanoic acid were detectable in 25
plasma samples from InCHIANTI participants. Fatty acid
methyl esters (FAME) were prepared through transesterifi-
cation. Separation of FAME was carried out on an HP-6890
gas chromatograph (Hewlett-Packard, Palo Alto, CA) with a
30-m fused silica column (HP-225 from Hewlett-Packard,
Palo Alto, CA). FAMEs were identified by comparison with
pure standards (NU Chek Prep Inc., Elysian, MA). For quan-
titative analysis of fatty acids as methyl esters, calibration
curves for FAME (ranging from C14:0 to C24:1) were pre-
pared by adding six increasing amounts of individual FAME
standards to the same amount of internal standard (C17:0;
50 g). The correlation coefficients for the calibration curves
of 20 fatty acids were in all cases higher than 0.998 in the
range of concentrations studied. Fatty acid concentration
was expressed as a percentage of total fatty acids based on
milligram per liter values. The coefficient of variation for all
fatty acids was on average 1.6% for intraassay and 3.3% for
interassay.
The amount of plasma fatty acids (ranging from C14:0 to
C24:1) is expressed as percentages of total fatty acids based
on mg/L values. In the present analysis, plasma saturated
fatty acids (SFAs), monounsaturated fatty acids (MUFAs),
total PUFAs, omega-3 fatty acid (n-3), omega-6 fatty acid 
(n-6), and the n-6/n-3 ratio were calculated. The n-3 and 
n-6 families of fatty acids account for more than 95% of to-
tal PUFAs and are named from the position of the first dou-
ble bond, located on the third or sixth carbon, respectively
from the terminal methyl group. The n-3 fatty acids included
-linolenic (ALA) (C18:3n3), EPA (C20:5n3), and docosa-
hexenoic (DHA) (C22:6n-3) acids. The total n-6 fatty acids in-
cluded: linoleic (LA) (C18:2n6), eicosadienoic (C20:2n6), and
arachidonic (AA) (C20:4n6) acids.
Measures of lower extremity performance
The Summary Physical Performance Battery (SPPB) that
was used to assess physical function at baseline and at fol-
low up consists of three lower extremity performance tests:
walking speed, standing balance, and ability to rise from a
chair. Walking speed was measured as the best performance
(shortest time in seconds) of two 4-m walks along a corri-
dor. For standing balance, participants were asked to stand
in three progressively more difficult positions for 10 sec each:
a position with feet side by side, a semitandem position, and
a full-tandem position. Performance was also timed for the
chair-stand test, which consisted of asking participants to
stand up from and sit down in a chair five times without us-
ing hands. Each physical performance test was categorized
into a five-level score, with 0 representing inability to do the
test and 4 representing the highest level of performance. A
summary performance measure ranging from 0 (poorest) to
12 (highest) was developed by summing categorical scores
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of the individual performance tests. Specific operational de-
finitions and scoring procedures for the SPPB have been de-
scribed in detail previously, and a cut-off score of 9 was
used to define impaired lower extremity performance.3,17
The 7-m walking task was performed at usual pace. Partici-
pants were instructed to walk at their usual pace and each
subject wore comfortable shoes for the entire walk test. The
use of aids was permitted if the subject normally used them
and could not walk without. Global cognitive performance
was assessed with the Mini-Mental State Examination
(MMSE).
Covariates
Participants were classified as nonsmokers or former
smokers versus current smokers based on self-report. Weight
was measured using a high-precision mechanical scale.
Standing height was measured to the nearest 0.1 cm. Body
mass index (BMI) was calculated as weight (kg)/height2
(m2). Average daily intake of energy (kcal) was estimated by
administering the European Prospective Investigation into
Cancer and Nutrition (EPIC) food frequency questionnaire,
which has been extensively validated in the Italian popula-
tion.18
Habitual physical activity was assessed using a modified
version of the EPIC physical activity questionnaire.19 This
test ranks the habitual level of physical activity on a scale of
1 to 7 (7  highest level of physical activity) and in the sta-
tistical models represents the covariate physical activity.
A lower leg peripheral quantitative computerized tomog-
raphy (pQCT) was performed in all participants using a re-
cent generation device (XCT 2000; Stratec, Pforzheim, Ger-
many) to evaluate calf muscle density and area. Data were
derived from standard 2.5-mm-thick transverse scans ob-
tained at 66% of the tibia length. The cross-sectional images
obtained from the scans were analyzed using BonAlyse soft-
ware (Jyvaskyla, Finland). Different tissues in the analysis
were separated according to diverse density thresholds. The
average density of muscle tissue was calculated and used in
the analysis as a potential confounder.
A physical examination was performed on all participants
by a specifically trained physician. Co-morbid chronic dis-
eases were ascertained according to standard, pre-estab-
lished criteria that combined information from self-reported
physician diagnoses, current pharmacological treatment,
medical records, clinical examinations, and blood tests. Co-
morbid chronic conditions included in the analyses were the
following diseases: dementia, heart failure, hypertension, di-
abetes, myocardial infarction, and stroke. Other covariates
that could possibly affect circulating fatty acids and physi-
cal performance included sociodemographic variables (age,
gender), plasma lipid concentrations (high-density lipopro-
tein cholesterol [HDL-C] and low-density lipoprotein cho-
lesterol [LDL-C], triglycerides), and inflammatory marker
(interleukin-6 [IL-6] and total insulin-like growth factor-1
[IGF-1]) plasma levels.
Calculation and statistical analysis
Descriptive results of continuous variables values are
presented as means  standard deviation or standard er-
ror. All variables were normally distributed with the ex-
ception of total n-3 fatty acid, ALA, EPA, DHA, PUFA,
MUFA, SFA, n-6/n-3 ratio, IL-6, and triglycerides, which
were log-transformed for analyses and back transformed
for data presentation. Analysis of covariance (ANCOVA)-
based tests were used to evaluate the differences in clinical
characteristics according to level of physical performance
after adjusting for age. Multivariate linear regression analy-
ses were performed testing the independent associations
between fatty acids (SFA, MUFA, PUFA, PUFA n-3, PUFA
n-6) and physical performance measures (SPPB, time to
complete a 7-m walk) after adjusting for age, gender, BMI,
smoking status, daily caloric intake, physical activity, mus-
cle density, number of chronic co-morbid conditions, and
plasma concentrations of total IGF-1, IL-6, HDL-C, LDL-C,
and triglycerides.
Logistic regression models were used to assess the pre-
dictive role of fatty acids on the development of impaired
lower extremity performance (SPPB  9) at follow up both
in unadjusted and fully adjusted analyses after excluding
those with a baseline SPPB score  9. Statistical analyses
were performed using the SPSS software package (Chicago,
IL). Multivariate linear regressions were performed using the
time to complete a 7-m walk at follow up as dependent vari-
able to test the independent association of age, gender, BMI,
smoking status, daily caloric intake, physical activity, mus-
cle density, time to complete a 7-m walk at baseline, num-
ber of co-morbid chronic conditions, and plasma concentra-
tions of total IGF-1, IL-6, HDL-C, LDL-C, and triglycerides.
Results
Cross-sectional analyses
The mean age of the participants was 68.8  15.7 years
and 55.7% were women. Age-adjusted characteristics of
study participants according to impaired versus normal
lower extremity performance are shown in Table 1. As ex-
pected, participants with a SPPB score 9 had on average a
better MMSE score than those with a SPPB score 9. Partic-
ipants in the higher-performance group also had higher lev-
els of total PUFA, n-3 PUFA, n-6 PUFA, while the levels of
SFA were significantly lower.
Linear multiple regression analyses testing the relation-
ship between fatty acid levels and physical performance pa-
rameters after adjusting for multiple confounders are re-
ported in Table 2. Total PUFA and n-3 fatty acid levels were
associated with a shorter time to complete a 7-m walk inde-
pendent of multiple confounders. A similar borderline sig-
nificant trend was also found for n-6 fatty acid levels and the
time to complete the 7-m walk. SFA levels were significantly
associated with a longer 7-m walking time completion.
PUFA and n-3 fatty acid levels were independently associ-
ated with better SPPB scores at baseline (Table 2).
Longitudinal analyses
At follow up, 12.9 % (n  114 of the 884) participants who
had a baseline SPPB score 9, developed impaired lower ex-
tremity physical performance (SPPB  9). Logistic regression
models were used to test the hypothesis that the level of dif-
ferent fatty acids would be associated with different risks of
developing poor lower extremity performance during 3
years of follow up. In unadjusted models, we found that
higher total PUFA, n-3, and n-6 fatty acid levels were in-
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versely associated with the development of low physical per-
formance (Table 3a). On the contrary, higher MUFA and n-
6/n-3 ratio levels were associated with a higher risk of de-
veloping poor performance (Table 3a). However, in fully
adjusted models, only n-3 fatty acid levels continued to be
inversely associated with the development of impaired phys-
ical performance, while the n-6/n-3 ratio continued to be as-
sociated with a higher risk of poor physical performance
(Table 3a).
In further logistic regression models that included the in-
dividual n-3 and n-6 fatty acids, we found that all n-3 fatty
acids were individually associated with lower probability of
developing lower extremity performance during the 3-year
follow up, whereas there were no significant associations for
the n-6 fatty acids (Table 3b).
Finally, we tested whether fatty acids concentrations were
associated with lower versus higher 7-m walking speed at
follow up. Interestingly, we found that the ratio n-6/n-3 was
associated with longer speed of the 3-year follow up, inde-
pendent of multiple confounders and baseline walking speed
(Table 4).
Discussion
Using data from a representative sample of the general
population, we found that in participants with better func-
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TABLE 2. LINEAR REGRESSION MODELS TESTING THE RELATIONSHIP OF BASELINE FATTY ACID LEVELS
WITH WALKING SPEED AND SPPB SCORE (n  1273)
Time to complete 7-m walk SPPB 
Fatty acidsa Beta SE p Beta SE p
Total PUFA 2.957 0.929 0.002 1.714 0.721 0.018
Total MUFA 0.556 0.859 0.518 0.334 0.667 0.616
SFA 2.647 1.062 0.013 1.271 0.832 0.127
n-3 fatty acids 0.724 0.304 0.018 0.524 0.237 0.027
n-6 fatty acids 0.054 0.028 0.051 0.025 0.021 0.252
Ratio n-6/n-3 0.463 0.304 0.128 0.379 0.236 0.109
All models were adjusted for age, sex, BMI, smoking, triglycerides , HDL-C, LDL-C, IL-6, total IGF-1, daily energy intake, physical activity,
skeletal muscle density, and number of chronic co-morbid diseases.
aLogarithm was used for all fatty acids except n-6 fatty acids.
PUFA, Polyunsaturated fatty acids; MUFA, monounsaturated fatty acids; SFA, saturated fatty acids. 
TABLE 1. BASELINE CHARACTERISTICS OF THE STUDY PARTICIPANTS ACCORDING TO PHYSICAL PERFORMANCE LEVEL
Summary physical performance battery score 
Overall 9 9
(n  1273) (n  330) (n  943) pa
BMI 27.2  4.1 27.7  4.5 27.0  4.0 0.584
MMSE 25.4  4.6 21.7  6.3 26.7  2.8 0.001
IGF-1 129.3  66.2 101.4  49.8 138.9  68.4 0.374
IL-6 (pg/mL) 2.03  3.94 3.17  6.93 1.63  1.92 0.001
LDL-C (mg/dL) 139.26  35.54 136.87  33.73 140.09  36.13 0.001
HDL-C (mg/dL) 55.72  14.94 54.50  16.61 56.14  14.30 0.206
Triglycerides (mg/dL) 125.89  76.60 138.30  102.55 121.58  64.74 0.323
Calf muscle density 71.5  3.7 69.2  3.9 72.2  3.4 0.001
Total PUFAb 38.35  5.09 36.36  5.56 39.05  4.73 0.001
Total MUFAb 31.05  3.95 32.57  3.81 30.52  3.86 0.055
n-3 fatty acidsb 3.35  0.98 3.15  0.98 3.43  0.97 0.003
n-6 fatty acids 32.96  4.66 31.14  4.97 33.59  4.37 0.002
Ratio n-6/n-3b 10.59  3.23 10.74  3.72 10.53  3.04 0.194
SFAb 30.58  2.84 31.09  3.17 30.41  2.69 0.004
Time to complete 7 m (sec) 6.55  3.44 10.20  5.65 5.49  1.01 0.001
Physical activity 3.36  1.10 2.59  1.12 3.63  0.96 0.001
Daily caloric intake (kcal/day) 2008  616 1714  485 2110  624 0.001
Number of co-morbidities 0.62  0.78 1.05  0.98 0.46  0.63 0.001
Values are expressed as means  standard deviation.
aAdjusted for age.
bLogarithm of % based on mg/L of total plasma fatty acids; see Methods section. 
BMI, Body mass index; MMSE, Mini Mental State Examination; IGF-1, insulin-like growth factor-1; IL-6, interleukin-6; LDL-C, low-density
lipoprotein cholesterol; HDL-C, high-density lipoprotein cholesterol; PUFA, polyunsaturated fatty acids; MUFA, monounsaturated fatty
acids; SFA, saturated fatty acids. 
tional status, baseline plasma concentrations of PUFAs were
significantly higher, while SFA and MUFA concentrations
were significantly lower, independent of age. Concentrations
of n-3 fatty acids, which probably reflect dietary intake, were
also associated with a lower probability of developing im-
paired lower extremity performance during the follow up.
Interestingly, an imbalance between n-6 and n-3 fatty acids
was associated with an increased risk of functional decline
and accelerated decline of walking speed after 3 years of fol-
low up. Overall, our findings support the notion that the
maintenance of high PUFA levels may prevent physical func-
tion decline in older persons.
The preventive role of PUFAs on several negative health
outcomes (especially n-3 fatty acids), which is probably at-
tributable to the positive effects on circulating lipids, blood
pressure, and inflammation, have been confirmed in many
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TABLE 3a. LOGISTIC REGRESSION MODELING THE EFFECT OF THE FATTY ACID LEVELS
ON SUBSEQUENT PHYSICAL PERFORMANCE DECLINE (n  884)
Model a Model b
Fatty acidc Odds ratio (95% CI) p value Odds ratio (95% CI) p value
Total PUFA 0.126 (0.025–0.625) 0.011 0.510 (0.034–7.686) 0.626
Total MUFA 18.276 (3.160–105.707) 0.001 1.484 (0.091–24.137) 0.781
SFA 1.472 (0.135–16.070) 0.751 3.274 (0.128–83.975) 0.474
n-3 fatty acids 0.275 (0.130–0.584) 0.001 0.207 (0.081–0.530) 0.001
n-6 fatty acids 0.949 (0.904–0.996) 0.033 1.025 (0.943–1.114) 0.565
Ratio n-6/n-3 2.543 (1.181–5.474) 0.017 5.228 (2.023–13.514) 0.001
TABLE 3b. LOGISTIC REGRESSION ANALYSES MODELING THE EFFECT OF EACH FATTY ACID CONCENTRATION
ON SUBSEQUENT PHYSICAL PERFORMANCE DECLINE (n  884)
Model a Model b
Fatty acidd Odds ratio (95% CI) p value Odds ratio (95% CI) p value
ALA (C18:3n3) 0.632 (0.403–0.991) 0.046 0.563 (0.330–0.960) 0.035
EPA (C20:5n3) 0.409 (0.196–0.851) 0.017 0.213 (0.081–0.557) 0.002
DHA (C22:6n-3) 0.370 (0.198–0.688) 0.002 0.378 (0.176–0.809) 0.012
LA (C18:2n6) 0.337 (0.096–1.188) 0.091 3.141 (0.398–24.799) 0.278
Eicosadienoic (C20:2n6) 0.972 (0.834–1.134) 0.718 0.937 (0.781–1.124) 0.486
AA (C20:4n6) 0.579 (0.243–1.381) 0.218 0.605 (0.201–1.817) 0.370
aUnadjusted models.
bFully adjusted that included the following independent variables: age, sex, BMI, smoking, triglycerides , HDL cholesterol, LDL choles-
terol, IL-6, total IGF-1, daily energy intake, physical activity, skeletal muscle density, and number of chronic co-morbid diseases. 
cLogarithm was used for all fatty acids except n-6 fatty acids.
dLogarithm was used for ALA, EPA, and DHA.
CI, confidence interval; PUFA, polyunsaturated fatty acids; MUFA, monounsaturated fatty acids; SFA, saturated fatty acids; ALA, 
-linolenic acid; EPA, eicosapentanoic acid; DHA, docosahexenoic acid; LA, linolenic acid; AA, arachidonic acid. 
TABLE 4. ADJUSTEDa AND FULLY ADJUSTEDb LINEAR MODELS TESTING THE RELATIONSHIP
OF BASELINE FATTY ACIDS WITH WALKING SPEED (n  884)
Time to complete 7-m walka Time to complete 7-m walkb
Fatty acidsc Beta SE p Beta SE p
Total PUFA 1.198 0.488 0.014 0.744 0.653 0.255
Total MUFA 1.147 0.476 0.016 0.459 0.555 0.409
SFA 0.068 0.678 0.920 0.140 0.688 0.839
n-3 fatty acids 0.554 0.211 0.009 0.439 0.199 0.028
n-6 fatty acids 0.029 0.014 0.040 0.009 0.019 0.639
Ratio n-6/n-3 0.064 0.020 0.050 0.396 0.199 0.037
aAdjusted for time to complete 7 m at baseline.
bFully adjusted included the following independent variables: age, sex, BMI, time to complete 7-m walk at baseline, smoking, triglycerides,
HDL-C, LDL-C, IL-6, total IGF-1, daily energy intake, physical activity, skeletal muscle density, and number of chronic co-morbid diseases.
cLogarithm was used for all fatty acids except n-6 fatty acids. 
SE, Standard error; PUFA, polyunsaturated fatty acids; MUFA, monounsaturated fatty acids; SFA, saturated fatty acids; HDL-C, high-
density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; IL-6, interleukin-6; IGF-1, insulin-like growth factor-1. 
clinical and epidemiological trials.20,21 By suggesting that
concentrations of PUFAs may be protective against the de-
terioration of lower extremity function in middle-aged and
older persons, our study expands this knowledge. It is par-
ticularly important to note that the class of fatty acids with
the most beneficial effect on physical performance is the
same that had been found inversely related to the circulat-
ing levels of proinflammatory markers in the same popula-
tion.9
The consumption of fish, the major source of EPA and
DHA, is low in the Chianti area and causes low variability
in long-chain n-3 fatty acids plasma levels. Considering that
there is such a low intake of fish consumption from the
InCHIANTI study population, the concentrations of EPA
and DHA most likely reflect a transformation from ALA. The
finding that the protective effect on physical performance
was found for ALA is reassuring. Indeed, it has been shown
that ALA, a source of DHA and EPA, provides similar health
benefits to longer-chain n-3 fatty acids, e.g., with respect to
neuronal function in animals,22 inflammation, and cardio-
vascular disease in humans.23
An interesting finding that deserves discussion is that both
n-3 and n-6 concentrations were significantly higher in the
better functional status group at baseline. However, in lin-
ear models testing the independent association between di-
verse fatty acids and the SPPB, the n-3 plasma levels con-
tinued to be associated with better physical performance
status. Furthermore, after testing the quality of polyunsatu-
rated fatty acids, as seen by the n-6/n-3 ratio, we found that
the n-6/n-3 ratio was cross-sectionally associated with poor
gait performance as well as with an increased risk of devel-
oping poor lower extremity performance over a 3-year fol-
low-up period. Indeed, an extensive literature search sug-
gests that n-6 fatty acids exert positive effects on diverse
health outcomes,24–26 although the importance of quality of
fatty acid intake as seen by the n-6/n-3 ratio remains con-
troversial. Nevertheless, the overall consensus is that an un-
balanced intake with a greater consumption of n-6 fatty acids
should be avoided.27 Indeed, our findings add insight to
those from a preclinical study demonstrating that the n-6/n-
3 ratio was significantly lower in animals with improved leg
muscle functioning.28 However, the role of fatty acids and
the impact of the n-6/n-3 ratio on physical decline should be
confirmed in intervention studies of fatty acid supplemen-
tation.
The potential mechanisms by which n-3 fatty acids may
positively affect cardiovascular health have been investi-
gated intensively in large epidemiological studies, which
have shown that a diet rich in n-3 fatty acid was associated
with lower-risk cardiovascular events and mortality. It has
been hypothesized that n-3 fatty acids favorably influence
the traditional cardiovascular risk factors, including lower-
ing plasma triglycerides and high blood pressure, as well 
as reducing neuro-cardiac instability and risk of arrhyth-
mias.29,30
Limited data exist on the effects of PUFAs on skeletal mus-
cle composition and function. There is evidence that a defi-
ciency in dietary PUFAs impair skeletal muscle performance
in animals,31,32 and some but not all studies found that a de-
ficiency in both n-6 and n-3 fatty acids was associated with
reduced performance in skeletal muscles.32 In addition, it has
been also demonstrated that fatty acid profiles from skeletal
muscle biopsies are strongly associated with diverse loco-
motor function in animals.32 Our findings also substantiate
findings from an animal study demonstrating that diet ex-
erted a greater effect on fatty acid skeletal muscle composi-
tion independently of exercise.33 Unfortunately the InCHI-
ANTI protocol did not use muscle biopsies; however n-3
fatty acids were inversely associated with a decline in phys-
ical function independently of physical activity.
Another possible mechanism by which n-3 fatty acids may
be acting on physical performance may be linked to meta-
bolic or respiratory response, and it may be hypothesized
that PUFAs may have a positive effect on the mitochondrial
biogenesis. Unfortunately, blood lactate concentrations or
oxygen consumption were not measured in the InCHIANTI
population.
Indeed our data suggest that n-3 fatty acids protect against
physical performance decline and that an imbalance of the
n-6/n-3 ratio is correlated with an increased risk on devel-
oping poor physical performance in humans. However, be-
cause of the observational nature of our study, it remains to
be clarified whether the preventive affect of PUFAs on phys-
ical function decline is due to their anti-inflammatory prop-
erties, their positive activity in chronic disease, or a direct ef-
fect on locomotor function.
To the best of our knowledge, this is the first investigation
to test the relationship between plasma levels of fatty acids
and physical performance measures in middle-aged and
older persons. It is important to underline that fatty acids
were measured directly from plasma and not estimated from
dietary reports or dietary supplementation. Only future tri-
als testing the role of fatty acid supplementation on physi-
cal performance and gait speed will determine whether the
supplementation of specific fatty acids in the diet may pre-
vent the development of physical impairment and disability
in older individuals.
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